Headway Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.95 M
About Headway Pharma
Headway Pharma Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 December 2013 and has a history of 11 years and one month. Its registered office is in Dehradun, Uttarakhand, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.95 M.
Ashish Arora and Avneet Kaur serve as directors at the Company.
Company Details
-
Location
Dehradun, Uttarakhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85190UR2013PTC000967
-
Company No.
000967
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Dec 2013
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Uttarakhand
Industry
What products or services does Headway Pharma Private Limited offer?
Headway Pharma Private Limited offers a wide range of products and services, including Third Party Manufacturing Consultancy, Pharmaceutical Third Party Manufacturing, Eye Drops, Carboxymethylcellulose Sodium Eye Drops, Ophthalmic Drops, Loteprednol Etabonate Ophthalmic Suspension, Tropicamide Drops, Digestive System Drugs & Medicines, Digestive Drugs, Fluorometholone Eye Drop.
Who are the key members and board of directors at Headway Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Arora
|
Director | 20-Dec-2013 | Current |
|
Avneet Kaur
|
Director | 20-Dec-2013 | Current |
Financial Performance of Headway Pharma.
Headway Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Headway Pharma?
In 2017, Headway Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.95 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 May 2020 | Others | ₹0.95 M | Open |
How Many Employees Work at Headway Pharma?
Unlock and access historical data on people associated with Headway Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Headway Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Headway Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.